KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials.

Thomas B Casale, Sarbjit S Saini, Moshe Ben-Shoshan, Ana M Giménez-Arnau, Jonathan A Bernstein, Koremasa Hayama, Nikhil Amin, Lacey B Robinson, Deborah Bauer, Paula Dakin, Elizabeth Laws, Allen Radin, Melanie Makhija

JAMA Dermatol 162(4) 350-358

PMID41706458
PMCIDPMC12917742
DOI10.1001/jamadermatol.2025.6023
发表日期2026-02-18
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线。
摘要

摘要

IMPORTANCE: Chronic spontaneous urticaria (CSU) is an inflammatory disease characterized by recurrent pruritic hives and/or angioedema. Many patients with CSU remain symptomatic despite standard-of-care, histamine 1-receptor antagonist (H1-AH) treatment. Dupilumab blocks IL-4/IL-13 signaling and is approved in multiple disease states associated with type 2 inflammation. In the phase 3 LIBERTY-CSU CUPID-A trial, dupilumab significantly reduced itch and hives severity in anti-immunoglobulin E (IgE)-naive patients with CSU uncontrolled with H1-AH. However, a replicate trial (CUPID-C) was required per US Food and Drug Administration registration requirements. OBJECTIVE: To further evaluate the efficacy and safety of dupilumab vs placebo in anti-IgE-naive patients with CSU uncontrolled by H1-AH. DESIGN, SETTING, AND PARTICIPANTS: The LIBERTY-CSU CUPID-C (2022-2024) was a randomized, placebo-controlled, double-blind, 24-week phase 3 trial using the same trial design as CUPID-A (2019-2021). CUPID-A and CUPID-C were performed in 10 countries in Asia, Europe, and North and South America with anti-IgE-naive patients aged 6 to 80 years with CSU uncontrolled with H1-AH. Data were analyzed from August to September 2024. INTERVENTIONS: Dupilumab or placebo. MAIN OUTCOMES AND MEASURES: In CUPID-C and pooled CUPID-A and -C analyses, change from baseline at week 24 in Itch Severity Score over 7 days (ISS7) or Urticaria Activity Score over 7 days (UAS7), with the other as a key secondary end point, per regional regulatory requirements. RESULTS: The CUPID-C analysis included 151 participants (mean [SD] age, 44.7 [16.9] years; 106 females [70.2%]), of whom 77 (51%) were taking H1-AH at a dosage higher than recommended, and 90 (59.6%) had a baseline UAS7 of 28 or greater. Significant improvements in ISS7 and UAS7 were observed with dupilumab vs placebo at week 24. Least squares mean (SE) changes were -8.64 (1.41) vs -6.10 (1.40), respectively (difference: -2.54 points [95% CI, -4.65 to -0.43]; P = .02) for ISS7 and -15.86 (2.66) vs -11.21 (2.65), respectively (difference: -4.65 points [95% CI, -8.65 to -0.65]; P = .02) for UAS7. CUPID-A and -C combined data (289 participants) demonstrated greater improvements in UAS7 and ISS7. Safety outcomes were generally consistent with the known dupilumab safety profile; 77 patients (53.5%) taking dupilumab vs 81 patients (55.9%) taking placebo reported treatment-emergent adverse events in the pooled analysis. CONCLUSIONS AND RELEVANCE: The CUPID-C randomized clinical trial confirmed CUPID-A findings, and pooled data demonstrated dupilumab significantly reduced urticaria activity by reducing itch and hives severity in anti-IgE-naive patients with CSU who remained symptomatic despite the use of H1-AH. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04180488.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Patient Disposition in the LIBERTY-CSU CUPID-C Randomized Clinical Trial IMP indicates investigational medicinal product; SAE, serious adverse event. a Refer to eMethods 2 in Supplement 4 for definitions of inclusion and exclusion criteria. b Study period was the study intervention period plus the postintervention follow-up period. c One participant discontinued the trial due to inefficacy of treatment and severe angioedema, and 1 patient was dismissed from the trial after missing last visit and being unavailable to reschedule. d One patient self-diagnosed an adverse event of asthma as associated with the IMP and requested withdrawal (although not due to a safety issue); 2 prohibited drugs were used to treat an SAE. e One patient completed visit 5 early (due to relocation of residence), and 1 patient preferred to be treated with omalizumab and withdrew from the study. f Primary analyses for CUPID-C were reported at the end of the treatment period. Patients continued with the safety follow-up period (off treatment).
非 KM Figure
Figure 2.Dupilumab Treatment and Early Improvement in Itch Severity and Urticaria Activity in Patients With Chronic Spontaneous Urticaria (CSU) Uncontrolled by Histamine 1–Receptor Antagonists in CUPID-C Error bars indicate SE values. ISS7 indicates Itch Severity Score during 7 days (range, 0-21 [higher scores indicate worsening itch]); LS, least squares; UAS7, Urticaria Activity Score over 7 days (scale, 0-42 [higher scores indicate worsening CSU activity]). a P < .05. b P < .01.
非 KM Figure